FDA Reviewing Dangers Associated With Advair and Serevent GlaxoSmithKline Asthma Drugs

FDA Reviewing Dangers Associated With Advair and Serevent GlaxoSmithKline Asthma Drugs

Stock Photo

(Best Syndication) The US Food and Drug Administration (FDA) is reviewing the GlaxoSmithKline asthma drugs Serevent and Advair. Regulators are concerned about potentially fatal but rare side effects, and an FDA panel is reviewing the safety of these drugs with children.

GSK is Europe’s largest drug maker, and the company believes the benefits of the drug outweigh the dangers. On November 27 the FDA’s Pediatric Advisory Committee will meet to weight those concerns, and the panel is scrambling to come up with a recommendation. Advair is the company’s biggest seller with $6.8 billion in sales last year.

By Marsha Quinn
Best Syndication Health Writer

Share/Save/Bookmark

      

Post to Facebook

Important: The material on Best Syndication is for informational purposes only and is not meant to be advice. Authors may have or will receive monetary compensation from the company's product/s mentioned. You should always seek professional advice before making any legal, financial or medical decisions and this website cannot substitute or replace any trained professional consultation.
Use of this site means that you agree to our TERMS OF SERVICE

Advertise On This Site
Copyright © 2006-2015 By Best Syndication All Rights Reserved